Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validating human induced pluripotent stem cell-specific quality control tests for the release of an intermediate drug product in a Good Manufacturing Practice quality system.
Novoa J, Westra I, Steeneveld E, Neves NF, Daleman L, Asensio AB, Davis RP, Carlotti F, Freund C, Rabelink T, Meij P, Wieles B. Novoa J, et al. Among authors: meij p. Cytotherapy. 2024 Sep;26(9):1105-1117. doi: 10.1016/j.jcyt.2024.04.004. Epub 2024 Apr 14. Cytotherapy. 2024. PMID: 38703154 Free article.
Good Manufacturing Practice-compliant human induced pluripotent stem cells: from bench to putative clinical products.
Novoa JJ, Westra IM, Steeneveld E, Fonseca Neves N, Arendzen CH, Rajaei B, Grundeken E, Yildiz M, van der Valk W, Salvador A, Carlotti F, Dijkers PF, Locher H, van den Berg CW, Raymond KI, Kirkeby A, Mummery CL, Rabelink TJ, Freund C, Meij P, Wieles B. Novoa JJ, et al. Among authors: meij p. Cytotherapy. 2024 Jun;26(6):556-566. doi: 10.1016/j.jcyt.2024.02.021. Epub 2024 Mar 5. Cytotherapy. 2024. PMID: 38483359 Free article.
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME, Santegoets SJ, Welters MJP, de Bruin L, Visser M, van der Minne CE, de Kok PM, Loof NM, Boekestijn S, Roozen I, Westra IM, Meij P, Van der Burg SH, Kroep JR. Verdegaal EME, et al. Among authors: meij p. J Immunother Cancer. 2023 Nov;11(11):e007697. doi: 10.1136/jitc-2023-007697. J Immunother Cancer. 2023. PMID: 37949617 Free PMC article.
Protective efficacy of short-term infection with Necator americanus hookworm larvae in healthy volunteers in the Netherlands: a single-centre, placebo-controlled, randomised, controlled, phase 1 trial.
Hoogerwerf MA, Janse JJ, Kuiper VP, van Schuijlenburg R, Kruize YC, Sijtsma JC, Nosoh BA, Koopman JR, Verbeek-Menken PH, Westra IM, Meij P, Brienen EA, Visser LG, van Lieshout L, Jochems SP, Yazdanbakhsh M, Roestenberg M. Hoogerwerf MA, et al. Among authors: meij p. Lancet Microbe. 2023 Dec;4(12):e1024-e1034. doi: 10.1016/S2666-5247(23)00218-5. Lancet Microbe. 2023. PMID: 38042152 Free article. Clinical Trial.
Safety and infectivity of female cercariae in Schistosoma-naïve, healthy participants: a controlled human Schistosoma mansoni infection study.
Koopman JPR, Houlder EL, Janse JJ, Casacuberta-Partal M, Lamers OAC, Sijtsma JC, de Dood C, Hilt ST, Ozir-Fazalalikhan A, Kuiper VP, Roozen GVT, de Bes-Roeleveld LM, Kruize YCM, Wammes LJ, Smits HH, van Lieshout L, van Dam GJ, van Amerongen-Westra IM, Meij P, Corstjens PLAM, Jochems SP, van Diepen A, Yazdanbakhsh M, Hokke CH, Roestenberg M. Koopman JPR, et al. Among authors: meij p. EBioMedicine. 2023 Nov;97:104832. doi: 10.1016/j.ebiom.2023.104832. Epub 2023 Oct 12. EBioMedicine. 2023. PMID: 37837930 Free PMC article.
Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands.
van der Plas JL, Kuiper VP, Bagchus WM, Bödding M, Yalkinoglu Ö, Tappert A, Seitzinger A, Spangenberg T, Bezuidenhout D, Wilkins J, Oeuvray C, Dhingra SK, Thathy V, Fidock DA, Smidt LCA, Roozen GVT, Koopman JPR, Lamers OAC, Sijtsma J, van Schuijlenburg R, Wessels E, Meij P, Kamerling IMC, Roestenberg M, Khandelwal A. van der Plas JL, et al. Among authors: meij p. Lancet Infect Dis. 2023 Oct;23(10):1164-1174. doi: 10.1016/S1473-3099(23)00212-8. Epub 2023 Jul 3. Lancet Infect Dis. 2023. PMID: 37414066 Clinical Trial.
Controlled Human Infection Studies: Proposals for guidance on how to design, develop and produce a challenge strain.
Bekeredjian-Ding I, Trouvin JH, Depraetere H, La C, Suvarnapunya AE, Bell A, Mann A, Meij P, Bethony JM, Schellhaas L, Nazziwa WB, Karikari-Boateng E, Prachumsri JS, Salmikangas P, Smith D, Stjärnkvist P, Van Molle W, Baay M, Neels P. Bekeredjian-Ding I, et al. Among authors: meij p. Biologicals. 2021 Nov;74:16-23. doi: 10.1016/j.biologicals.2021.09.002. Epub 2021 Oct 5. Biologicals. 2021. PMID: 34620540 Free article.
Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study.
Reinders MEJ, Groeneweg KE, Hendriks SH, Bank JR, Dreyer GJ, de Vries APJ, van Pel M, Roelofs H, Huurman VAL, Meij P, Moes DJAR, Fibbe WE, Claas FHJ, Roelen DL, van Kooten C, Kers J, Heidt S, Rabelink TJ, de Fijter JW. Reinders MEJ, et al. Among authors: meij p. Am J Transplant. 2021 Sep;21(9):3055-3065. doi: 10.1111/ajt.16528. Epub 2021 Mar 18. Am J Transplant. 2021. PMID: 33565206 Free PMC article. Clinical Trial.
Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial.
van der Kooij MK, Verdegaal EME, Visser M, de Bruin L, van der Minne CE, Meij PM, Roozen ICFM, Jonker MA, van den Bosch S, Liefers GJ, Speetjens FM, van der Burg SH, Kapiteijn E. van der Kooij MK, et al. Among authors: meij pm. BMJ Open. 2020 Nov 24;10(11):e044036. doi: 10.1136/bmjopen-2020-044036. BMJ Open. 2020. PMID: 33234662 Free PMC article.
52 results